Cumulative incidence of anemia, thrombocytopenia, and marked leukocytosis in PMF patients stratified according to their driver mutation. The thresholds for hemoglobin level and WBC count are those of the IPSS,³  whereas that for PLT count is the lower limit of normal range. Cumulative incidences were estimated with a competing risk approach, considering death for any cause as a competing event. Vertical tick marks indicate right-censored patients. (A) Cumulative incidence of anemia (hemoglobin <10 g/dL). CALR-mutant patients had a lower incidence of anemia compared with the remaining patients (maximum P value equal to .004). (B) Cumulative incidence of thrombocytopenia (PLT count <100 × 10⁹/L). The cumulative incidence of thrombocytopenia was significantly lower in CALR-mutant patients compared with the remaining ones (P < .001 in all comparisons). (C) Cumulative incidence of marked leukocytosis (WBC count >25 × 10⁹/L). The cumulative incidence of marked leukocytosis was significantly lower in CALR-mutant patients compared with JAK2-mutant (P = .004) or triple-negative patients (P < .001).